DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Market Closed - Deutsche Boerse AG 13:43:45 2024-06-07 EDT | ||
| 1.09 EUR | +2.83% |
|
| Current month | +26.74% | ||
| 1 month | +49.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 1.09 | +2.83% |
| 24-06-06 | 1.06 | +2.91% |
| 24-06-05 | 1.03 | +8.42% |
| 24-06-04 | 0.95 | +6.74% |
| 24-06-03 | 0.89 | +3.49% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 01:43 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM51T1 |
| ISIN | DE000VM51T14 |
| Date issued | 2023-11-27 |
| Strike | 130 $ |
| Maturity | 2024-12-20 (196 Days) |
| Parity | 10 : 1 |
| Emission price | 0.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.09 € |
|---|---|
| Lowest since issue | 0.24 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Certificates
- Certificat
